Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Henriksen

Showing results (191-200 of 193) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 193 results.
Clinical Chemistry and Laboratory Medicine|January 3, 2025
Behind the scenes of EQA - characteristics, capabilities, benefits and assets of external quality assessment (EQA)Christoph Buchta, Rachel Marrington, Barbara De la Salle, et al.
Clinical Chemistry and Laboratory Medicine|January 3, 2025
Behind the scenes of EQA - characteristics, capabilities, benefits and assets of external quality assessment (EQA)Christoph Buchta, Rachel Marrington, Barbara De la Salle, et al.
Journal of Internal Medicine|February 15, 2019
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trialG L Goll, K K Jørgensen, J Sexton, et al.
Pageof 20

Showing results (191-200 of 193) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 193 results.
Clinical Chemistry and Laboratory Medicine|January 3, 2025
Behind the scenes of EQA - characteristics, capabilities, benefits and assets of external quality assessment (EQA)Christoph Buchta, Rachel Marrington, Barbara De la Salle, et al.
Clinical Chemistry and Laboratory Medicine|January 3, 2025
Behind the scenes of EQA - characteristics, capabilities, benefits and assets of external quality assessment (EQA)Christoph Buchta, Rachel Marrington, Barbara De la Salle, et al.
Journal of Internal Medicine|February 15, 2019
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trialG L Goll, K K Jørgensen, J Sexton, et al.
Pageof 20